| A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic … NE Algranati, S Sy, M Modi Hepatology 30 (4 Pt 2), 190A, 1999 | 110 | 1999 |
| Use of a sparse sampling study design to assess transfer of tramadol and its O‐desmethyl metabolite into transitional breast milk KF Ilett, MJ Paech, M Page‐Sharp, SK Sy, JH Kristensen, R Goy, S Chua, ... British journal of clinical pharmacology 65 (5), 661-666, 2008 | 79 | 2008 |
| Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs MT Heinrichs, RJ May, F Heider, T Reimers, SKB Sy, CA Peloquin, ... The International Journal of Mycobacteriology 7 (2), 156-161, 2018 | 63 | 2018 |
| Pharmacokinetics and pharmacodynamics in antibiotic dose optimization SKB Sy, L Zhuang, H Derendorf Expert opinion on drug metabolism & toxicology 12 (1), 93-114, 2016 | 63 | 2016 |
| Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression SK Sy, A Ciaccia, W Li, EA Roberts, A Okey, W Kalow, BK Tang European journal of clinical pharmacology 58, 357-365, 2002 | 52 | 2002 |
| Pharmacokinetics of para-Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug … L de Kock, SKB Sy, B Rosenkranz, AH Diacon, K Prescott, KR Hernandez, ... Antimicrobial Agents and Chemotherapy 58 (10), 6242-6250, 2014 | 46 | 2014 |
| Clinical pharmacokinetics and pharmacodynamics of ceftazidime–avibactam combination: a model-informed strategy for its clinical development SKB Sy, L Zhuang, S Sy, H Derendorf Clinical Pharmacokinetics 58, 545-564, 2019 | 43 | 2019 |
| Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae J Albiero, SKB Sy, J Mazucheli, SM Caparroz-Assef, BB Costa, JLB Alves, ... Antimicrobial Agents and Chemotherapy 60 (7), 4128-4139, 2016 | 42 | 2016 |
| Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk S Salman, SKB Sy, KF Ilett, M Page-Sharp, MJ Paech European journal of clinical pharmacology 67, 899-908, 2011 | 41 | 2011 |
| In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms SKB Sy, ME Beaudoin, L Zhuang, KI Löblein, C Lux, M Kissel, R Tremmel, ... Journal of Antimicrobial Chemotherapy 71 (7), 1866-1880, 2016 | 40 | 2016 |
| Pharmacodynamic attainment of the synergism of meropenem and fosfomycin combination against Pseudomonas aeruginosa producing metallo-β-lactamase J Albiero, J Mazucheli, JPR Barros, MMA Szczerepa, SAB Nishiyama, ... Antimicrobial Agents and Chemotherapy 63 (6), 10.1128/aac. 00126-19, 2019 | 34 | 2019 |
| Pharmacodynamic evaluation of fosfomycin against Escherichia coli and Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin activities NH Fedrigo, J Mazucheli, J Albiero, DR Shinohara, FG Lodi, ... Antimicrobial Agents and Chemotherapy 61 (8), 10.1128/aac. 02498-16, 2017 | 31 | 2017 |
| Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant … SKB Sy, L Zhuang, H Xia, ME Beaudoin, VJ Schuck, H Derendorf CPT: Pharmacometrics & systems pharmacology 6 (3), 197-207, 2017 | 31 | 2017 |
| N-Acetyltransferase Genotypes and the Pharmacokinetics and Tolerability of para-Aminosalicylic Acid in Patients with Drug-Resistant Pulmonary Tuberculosis SKB Sy, L de Kock, AH Diacon, CJ Werely, H Xia, B Rosenkranz, ... Antimicrobial Agents and Chemotherapy 59 (7), 4129-4138, 2015 | 31 | 2015 |
| Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation MT Heinrichs, GL Drusano, DL Brown, MS Maynard, SKB Sy, KH Rand, ... International journal of antimicrobial agents 53 (3), 275-283, 2019 | 30 | 2019 |
| Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model L Zhuang, Y He, H Xia, Y Liu, SKB Sy, H Derendorf Journal of Antimicrobial Chemotherapy 71 (4), 1012-1021, 2016 | 30 | 2016 |
| Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors M Yu, Z Gao, X Dai, H Gong, L Zhang, X Chen, DF Zhong, SKB Sy Clinical pharmacokinetics 56, 65-76, 2017 | 29 | 2017 |
| Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard … TC Menegucci, NH Fedrigo, FG Lodi, J Albiero, SAB Nishiyama, ... Microbial drug resistance 25 (9), 1266-1274, 2019 | 27 | 2019 |
| Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model SKB Sy, L Zhuang, ME Beaudoin, P Kircher, MAM Tabosa, ... Journal of Antimicrobial Chemotherapy 72 (4), 1109-1117, 2017 | 27 | 2017 |
| A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa SKB Sy, L Zhuang, H Xia, ME Beaudoin, VJ Schuck, WW Nichols, ... Journal of Antimicrobial Chemotherapy 73 (5), 1295-1304, 2018 | 26 | 2018 |
